YS Biopharma
at a glance robust revenue growth of rabies vaccine driven by rising price and market share expansion which was administered million doses with proven efficacy and safety pika covid vaccine potential to become a prophylactic and therapeutic vaccine against multiple virus variants pika rabies vaccine a who designated innovative vaccine featuring accelerated regimen and superior efficacy and potential to elevate the standard of care strong capabilities underpinned by innovative pika technology platform established infrastructure and in vaccine and production new product launch and commercialization | YS Biopharma
Company
Deck Type
Deck date
September 2022
Slide
22 of 37
Related slides by other companies
Blue Water Vaccines
Results
October 2022
a potential platform for combination vaccines | Blue Water Vaccines
Enochian Biosciences
Investor Presentation
January 2024
leading efficacy for therapeutic vaccines in preclinical models for human solid tumors treated animals compared to controls | Enochian Biosciences
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights